Clinical Trial Update: The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel [NA]

View source ↗

Summary

Clinical trial update describing a neoadjuvant regimen for early high-risk triple-negative breast cancer in HRD-positive tumors using a combination of iparomlim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Lynparza (olaparib)
• PACLITAXEL (PACLITAXEL)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Harbin Medical University | Conditions: Triple Negative Breast Cancer (TNBC) | NA | Status: NOT_YET_RECRUITING